CRISPR's Potential: A Cure for HIV?

Researchers are conducting a clinical trial to test the safety of a new gene therapy called EBT-101, which uses CRISPR-Cas9 gene editing to potentially cure HIV. This is the first time a gene-editing treatment for HIV has been tried in humans. While initial results show no toxic effects or serious adverse events, it is still unknown if EBT-101 can effectively target latent HIV cells and control the virus in humans. The trial will continue to test additional doses of EBT-101 for safety and determine if the virus remains suppressed when patients are taken off current HIV treatments. Long-term follow-up studies will be conducted to assess any potential adverse effects.